glp-1 pediatric Researchers at UC Irvine issue a warning that GLP-1RAs may be dangerous for children GLP-1 agonists in pediatric obesity:
Description
Many communities offer medication take-back programs, and the FDA provides guidance on safe home disposal when take-back options are unavailable
Clinical review of subcutaneous semaglutide for obesity
However, these drugs do not come without side effects
If the reduction in body weight and the improvement of glycemic control are crucial factors in determining the effects of GLP-1 on NAFLD, direct pharmacological mechanisms could also be involved
Higher vagal tone generally correlates with better stress resilience
10.4049/jimmunol.1103801 39
